Hints and tips:
Related Special Reports
...Timothy Mackey, professor of global health at University of California San Diego, predicted that other pharma companies would probably follow Eli Lilly and Pfizer....
...Ogilvy, which has previously worked with a host of pharma groups including Pfizer and Johnson & Johnson, is launching a business that offers vetted influencers to talk about illnesses and possible solutions...
...Powell said investors worried that Pfizer had paid a lot for what it had bought....
...Health authorities had also hoped it could help sway sceptics who preferred not to receive an mRNA vaccine, though demand has since collapsed....
...Pfizer said discussions had been conducted “in good faith by all parties” and that it was committed to finding “pragmatic solutions” to address public health....
...“We are committed to finding pragmatic solutions to address public health and the evolving pandemic needs, while ensuring Pfizer and BioNTech continue to meet all of their contractual obligations regarding...
...Pfizer is “trying to leverage some of that brand equity that they got the world spinning again”, said Markus Saba, a marketing professor at the University of North Carolina Center for the Business of Health...
...Pfizer and BioNTech will dispute Moderna’s ability to withdraw the pledge when it did, given the World Health Organization did not declare the end of the “global health emergency” until March 2023....
...Its vaccine, a more traditional protein-based formulation combined with an adjuvant to boost its effectiveness, has been pitched to patients as a counterpoint to mRNA jabs from BioNTech/Pfizer and Moderna...
...Products and Alibaba Health Information Technology....
...Novavax is this year rolling out its second product: a malaria vaccine approved by the World Health Organization, which will help to grow its revenues from $531.4mn last year to a projected $854.2mn this...
...Pfizer needs to convince investors that Covid-19 treatments are not its only source of success. So far, it has failed....
...More than a billion dollars worth of Pfizer’s Covid-19 antiviral drugs procured in Europe have been wasted, according to health data, as tight controls over who can receive the medication left millions of...
...In response to these concerns, Pfizer initiated a significant cost-cutting programme, worth at least $4bn....
...Pfizer will not take the twice-daily formulation into late-stage trials but will focus on developing a pill to be taken once a day....
...Panuwat’s company, Medivation, was bought in 2016 by Pfizer for $14bn. But the stock he purchased at the time was not that of Medivation....
Case studies in best practice among general counsel and company legal teams in North America
...The US federal drug regulator has approved new Covid-19 boosters from Moderna and Pfizer, as it moves to contain infections from spreading more quickly in the US....
...Yet Pfizer’s $19bn in Paxlovid sales were almost a fifth of its 2022 total....
...BioNTech has written down about €900mn on its Covid-19 vaccines because of lower than expected demand for the shots it developed with partner Pfizer....
...The rise and fall of WeightWatchers Sistani describes the new WW as a judgment-free “weight health” company embracing “a full spectrum of solutions”....
...Pfizer will keep the commercialisation rights outside the US and Japan. Roivant owns 75 per cent of Telavant, while Pfizer owns 25 per cent....
...Huge demand for GLP-1s, the lucrative new class of diabetes and weight-loss drugs that include Wegovy and Zepbound, is testing the capacity of plants capable of the formulation of pharmaceutical solutions...
...Shares in Pfizer added about 1 per cent on Friday, while Seagen was up about 0.9 per cent....
...“Nobody at Pfizer ever told Mr Dagar, who was on the ‘blinded’ side, the results of the Paxlovid trial,” he added....
International Edition